Hepatitis C clinic operated by infectious disease specialists at a comprehensive cancer center: Help is on the way

Clinical Infectious Diseases

Volumn 54, Issue 5, 2012, Pages 740-742

  Torres, Harrys A ^a   Adachi, Javier A ^a   Roach, Lillian R ^a   Smith, Kathleen M ^a   Mahale, Parag S ^a   Davila, Marta ^a   Raad, Issam I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; CANCER CENTER; CANCER PATIENT; CANCER SURVIVOR; CHRONIC LIVER DISEASE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LIVER CELL CARCINOMA; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

CANCER CARE FACILITIES; HEPATITIS C; HUMANS; INFECTIOUS DISEASE MEDICINE; NEOPLASMS; PRACTICE MANAGEMENT, MEDICAL; SPECIALIZATION;

EID: 84863421962     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir930     Document Type: Letter

References (10)

1. Jensen DM. A new era of hepatitis C therapy begins. N Engl J Med 2011; 364:1272-4.
2. Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: Report from the hepatitis B and C summit conference. J Viral Hepat 2011; 18:1-16.
3. Torres HA, Mahale P, Davila M, et al. Hepatitis C virus infection in cancer patients: the story of a forgotten population. In: Abstracts of the 48th Annual Meeting of the Infectious Diseases Society of America; October 21-24, 2010; Vancouver, Canada. Abstract 729.
4. Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996; 347:92-3.
5. Arcaini L, Merli M, Passamonti F, et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am J Hematol 2010; 85:46-50.
6. Miyatake H, Kobayashi Y, Iwasaki Y, et al. Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma [published online ahead of print 12 October 2011]. Dig Dis Sci 2011; doi:10.1007/s10620-011-01934-1.
7. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant 2009; 15:1143-238.
8. Ramos CA, Saliba RM, de Pádua L, et al. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 2009; 94: 249-57.
9. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-74.
10. Huang JF, Yu ML, Huang CF, et al. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis C patients with hepatocellular carcinoma post curative therapies-a multicenter prospective trial. J Hepatol 2011; 54:219-26.